Winst gevend schreef op 2 juli 2021 12:55:
Evaluate Vantage:
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Pharming could well steal a march on market leader Takeda
by investing in gene therapy now; the Japanese giant, whose Takhzyro
is forecast to hit blockbuster status this year, does not appear
to have a stake in any such technology in HAE.
Nearer term-innovation in HAE includes Kalvista and Pharvaris's oral projects
in both the acute and prophylactic space.
Several groups are looking at longer-acting mechanisms, including CSL
with its once monthly MAb, while in vivo gene editing and RNAi projects
are in early stages elsewhere.
Should these approaches succeed a less convenient gene therapy
could well prove useful only for the most severe cases,
but with much work still to be done that remains a debate for the future.
www.evaluate.com/vantage/articles/new...